YOLFTbeta
Hikma Pharmaceuticals PLC

Hikma Pharmaceuticals PLC

HIK · LSE · Healthcare / Drug Manufacturers - Specialty & Generic

1,635.00GBX-15.00 (-0.91%)

Price History

Full chart

Market Stats

Previous Close1,650.00
Open1,655.00
Day Range1,633.00 – 1,655.00
52-Week Range1,134.72 – 1,782.86
Volume353.89K
Market Cap3.27B
P/E (TTM)11.88
Forward P/E8.42
EPS1.33
Dividend Yield4.07%
Beta0.66
50-Day Avg1,606.92
200-Day Avg1,490.73

About

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products. The company operates through three segments: Injectables, Hikma Rx, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The Hikma Rx segment offers oral, respiratory, and other generic and specialty products for the retail market. It provides its products in various therapeutic areas, including respiratory, oncology, and pain management. The company also offers its products in solid, semi-solid, liquid, and injectable dosage forms. It operates in the United Kingdom, Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, United Kingdom.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOH.E Said Darwazah
  • Employees9.50K
  • Headquarters10 Portman Square, London, United Kingdom, W1H 6AZ, UK
  • Websitehttps://www.hikma.com

Leadership

  • H.E Said DarwazahChief Executive Officer · b. 1957
  • Mr. Mazen Samih Taleb DarwazehExecutive Vice Chairman & Deputy CEO of MENA · b. 1958
  • Mr. Khalid Walid Hussni Al Nabilsi C.P.A.Deputy CEO of North America and Europe & Director · b. 1972
  • Mr. Areb AL KURDIVP, Group Financial Controller & Acting CFO · b. 1974
  • Ms. Patricia BousfieldChief Information Officer
  • Mr. Guy FeatherstoneAssociate Director of Investor Relations
  • Mr. Samuel ParkGeneral Counsel
  • Mr. Bassam Wael Rushdi Kanaan CFA, CPAExecutive Vice President of Corporate Development and M&A · b. 1965
  • Mr. Hussein Omar ArkhaghaChief People Officer
  • Ms. Susan RingdalExecutive Vice President of Strategic Planning & Global Affairs

Financials

Income Statement

Currency: USD2002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue85.50M105.15M212.38M262.21M317.02M448.80M580.66M636.88M730.94M918.02M1.11B1.36B1.49B1.44B1.95B1.94B2.07B2.21B2.34B2.55B2.52B2.88B3.13B3.35B
Growth (%)-+22.98%+101.98%+23.47%+20.90%+41.57%+29.38%+9.68%+14.77%+25.60%+20.80%+23.08%+9.08%-3.29%+35.42%-0.72%+6.92%+6.62%+6.07%+9.06%-1.41%+14.22%+8.77%+7.10%
Cost of Revenue40.58M51.57M103.94M126.42M158.49M227.26M324.17M332.46M373.59M522.68M605.00M648.00M670.00M622.00M1.00B1.02B1.07B1.11B1.13B1.25B1.25B1.47B1.71B1.91B
Gross Profit44.92M53.58M108.44M135.79M158.53M221.53M256.48M304.43M357.34M395.35M504.00M717.00M819.00M818.00M950.00M915.00M1.00B1.10B1.21B1.30B1.26B1.41B1.42B1.44B
Gross Margin52.54%50.96%51.06%51.79%50.01%49.36%44.17%47.80%48.89%43.07%45.45%52.53%55.00%56.81%48.72%47.26%48.50%49.80%51.82%50.96%50.26%48.94%45.25%43.03%
Operating Expense22.46M22.59M45.72M66.58M83.28M129.13M175.80M197.13M222.25M276.66M337.00M322.00M400.00M425.00M549.00M579.00M576.00M613.00M673.00M667.00M674.00M1.04B803.00M861.08M
Operating Income22.46M30.99M62.72M69.21M75.25M92.40M80.68M107.29M135.09M118.69M167.00M395.00M419.00M393.00M401.00M336.00M428.00M486.00M540.00M634.00M591.00M367.00M612.00M579.92M
Operating Margin26.27%29.47%29.53%26.39%23.74%20.59%13.89%16.85%18.48%12.93%15.06%28.94%28.14%27.29%20.56%17.36%20.68%22.02%23.07%24.83%23.48%12.77%19.57%17.32%
EBITDA28.71M34.63M68.64M79.70M94.35M117.86M113.86M141.09M173.49M154.65M213.00M457.00M481.00M459.00M506.00M554.00M527.00M584.00M631.00M744.00M485.00M791.00M787.00M845.00M
EBITDA Margin33.58%32.94%32.32%30.39%29.76%26.26%19.61%22.15%23.73%16.85%19.21%33.48%32.30%31.87%25.95%28.62%25.46%26.46%26.95%29.14%19.27%27.51%25.17%25.23%
Net Income10.50M17.59M37.46M43.87M54.52M62.58M57.13M77.68M98.85M80.11M100.00M212.00M278.00M252.00M155.00M-843.00M282.00M486.00M431.00M421.00M188.00M190.00M359.00M410.43M
Net Income Margin12.28%16.73%17.64%16.73%17.20%13.94%9.84%12.20%13.52%8.73%9.02%15.53%18.67%17.50%7.95%-43.54%13.62%22.02%18.41%16.49%7.47%6.61%11.48%12.26%
R&D3.01M4.13M9.67M16.51M18.29M19.34M22.17M16.84M23.61M31.22M34.00M39.00M55.00M36.00M150.00M121.00M147.00M150.00M137.00M143.00M144.00M149.00M141.00M154.17M
R&D as % of Total Revenue3.53%3.92%4.55%6.30%5.77%4.31%3.82%2.64%3.23%3.40%3.07%2.86%3.69%2.50%7.69%6.25%7.10%6.80%5.85%5.60%5.72%5.18%4.51%4.60%
Interest Expense2.55M1.90M3.83M5.21M4.96M10.84M17.55M12.83M13.86M23.37M22.00M37.00M38.00M57.00M104.00M60.00M80.00M67.00M56.00M40.72M77.00M90.00M75.00M108.22M
Interest Expense % of Total Revenue2.98%1.81%1.80%1.99%1.56%2.41%3.02%2.01%1.90%2.55%1.98%2.71%2.55%3.96%5.33%3.10%3.86%3.04%2.39%1.59%3.06%3.13%2.40%3.23%

Balance Sheet

Currency: USD2002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-06-302023-12-312024-12-312025-12-31
Total Assets94.86M117.86M246.48M397.96M488.36M894.04M966.46M1.02B1.12B1.58B1.73B1.93B2.25B2.60B4.36B3.39B3.50B3.93B4.13B4.37B4.47B-4.68B5.13B5.67B
Total Liabilities46.84M57.39M101.31M110.48M138.56M469.38M357.46M339.46M365.52M777.01M882.26M895.00M1.03B1.25B1.95B1.86B1.80B1.80B1.99B1.91B2.32B-2.47B2.81B3.07B
Total Equity47.75M60.08M142.49M283.88M345.07M418.48M603.21M675.88M743.92M776.58M832.65M1.02B1.20B1.34B2.40B1.51B1.69B2.12B2.13B2.45B2.13B-2.20B2.31B2.59B
Cash12.10M22.02M41.41M141.08M91.56M34.53M62.73M65.66M62.72M94.72M176.51M168.00M280.00M553.00M155.00M227.00M276.00M442.00M323.00M426.00M270.00M-205.00M188.00M328.12M
Total Debt22.54M15.84M63.01M54.15M66.61M341.35M234.43M184.94M167.42M519.18M584.74M442.00M562.00M728.00M860.00M777.00M637.00M685.00M932.00M846.00M1.28B-1.19B1.31B1.60B
Net Debt10.44M-6.18M21.60M-86.93M-24.95M306.82M171.70M119.27M104.71M424.47M408.23M274.00M282.00M175.00M705.00M550.00M361.00M243.00M609.00M420.00M1.01B-986.00M1.12B1.28B

Cash Flow

Currency: USD2002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow14.35M18.35M32.84M32.71M29.99M43.12M57.87M105.52M138.79M102.64M182.16M337.00M425.00M366.00M293.00M443.00M430.00M472.00M464.00M638.00M530.00M608.00M564.00M366.53M
Investing Cash Flow-11.81M-13.00M-25.40M-16.35M-66.22M-119.49M-220.55M-96.16M-79.08M-283.39M-101.02M-115.00M-342.00M-162.00M-695.00M-151.00M-96.00M-151.00M-283.00M-238.00M-607.00M-333.00M-381.00M-402.27M
Financing Cash Flow-4.76M6.00M-5.43M77.32M-14.82M19.19M196.20M-6.52M-60.46M213.34M5.95M-229.00M30.00M77.00M19.00M-220.00M-278.00M-155.00M-298.00M-287.00M-58.00M-337.00M-188.00M59.22M
Capital Expenditure0021.33M23.98M52.44M54.99M65.52M40.38M53.20M78.00M90.19M59.00M91.00M82.00M122.00M107.00M107.00M186.00M224.00M229.00M225.00M169.00M165.00M201.13M
Free Cash Flow14.35M18.35M11.51M8.73M-22.45M-11.87M-7.65M65.14M85.59M24.64M91.97M278.00M334.00M284.00M171.00M336.00M323.00M286.00M240.00M409.00M305.00M439.00M399.00M165.40M
Dividends Paid--3.77M17.80M6.99M12.83M14.15M16.12M23.07M25.20M26.55M39.00M55.00M64.00M77.00M79.00M84.00M97.00M109.00M120.00M125.00M137.00M175.00M188.88M
FCF to OCF100.00%100.00%35.05%26.68%-74.85%-27.53%-13.21%61.73%61.67%24.01%50.49%82.49%78.59%77.60%58.36%75.85%75.12%60.59%51.72%64.11%57.55%72.20%70.74%45.13%
Dividend Paid to FCF--32.71%203.94%-31.13%-108.11%-185.08%24.75%26.96%102.28%28.87%14.03%16.47%22.54%45.03%23.51%26.01%33.92%45.42%29.34%40.98%31.21%43.86%114.20%

Earnings

Report DateMar 12, 2014Aug 20, 2014Mar 11, 2015Aug 19, 2015Mar 16, 2016Aug 24, 2016Mar 15, 2017Aug 17, 2017Mar 14, 2018Aug 15, 2018Mar 13, 2019Aug 9, 2019Mar 11, 2020Aug 7, 2020Feb 25, 2021Aug 6, 2021Feb 24, 2022Aug 4, 2022Feb 23, 2023Mar 19, 2025Aug 7, 2025Feb 25, 2027
EPS Estimate0.000.630.000.670.500.230.370.440.440.410.000.640.710.74-1.220.900.980.950.820.001.21-
EPS Actual0.000.000.000.000.580.250.400.29-4.000.000.000.000.000.000.000.000.000.000.000.601.07-
Surprise--100.00%--100.00%16.00%8.70%8.11%-34.09%-1009.09%-100.00%--100.00%-100.00%-100.00%100.00%-100.00%-100.00%-100.00%-100.00%--11.57%-
Timing-----------------Pre-marketPre-market-After-hoursPre-market

Key Statistics & Ratios

Market Cap3.27B
Enterprise Value4.55B
Trailing P/E11.88
Forward P/E8.42
PEG Ratio2.38
Price / Sales0.96
Price / Book1.75
EPS1.33
Book Value8.80
Revenue (TTM)3.42B
Gross Profit (TTM)1.51B
EBITDA879.00M
Profit Margin11.32%
Operating Margin23.50%
Return on Equity15.41%
Return on Assets7.47%
Shares Outstanding206.97M
Shares Float146.44M
Beta0.66
Dividend Yield4.07%
Dividend Rate0.64
Payout Ratio46.87%

Dividends

20262×
0.29Aug 13, 20260.35Mar 19, 2026
20252×
0.27Aug 14, 20250.37Mar 20, 2025
20242×
0.24Aug 15, 20240.37Mar 21, 2024
20232×
0.20Aug 10, 20230.30Mar 23, 2023
20222×
0.16Aug 18, 20220.26Mar 17, 2022
20212×
0.13Aug 19, 20210.25Mar 18, 2021
20202×
0.12Aug 20, 20200.24Mar 19, 2020
20192×
0.14Aug 22, 20190.20Apr 4, 2019
20182×
0.09Aug 23, 20180.16Apr 5, 2018
20172×
0.09Aug 24, 20170.16Apr 6, 2017
20162×
0.08Sep 1, 20160.14Apr 7, 2016
20152×
0.07Aug 27, 20150.13Apr 16, 2015